



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 830 864 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see page(s) 3, 8-10

(51) Int Cl.7: **A61K 31/5513**, A61K 31/137,
A61P 25/18
// (A61K31/55, 31:13)

(48) Corrigendum issued on:
03.09.2003 Bulletin 2003/36

(45) Date of publication and mention
of the grant of the patent:
29.01.2003 Bulletin 2003/05

(21) Application number: **97307375.2**

(22) Date of filing: **22.09.1997**

(54) **Combination therapy for treatment of psychoses**

Kombinationstherapie für die Behandlung von Psychosen

Thérapie combinée pour le traitement de psychoses

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE
Designated Extension States:
AL LT LV RO SI

(30) Priority: **23.09.1996 US 26884 P**

(43) Date of publication of application:
25.03.1998 Bulletin 1998/13

(60) Divisional application:
02016238.4 / 1 256 345

(73) Proprietor: **ELI LILLY AND COMPANY**
Indianapolis, Indiana 46285 (US)

(72) Inventors:
• **Bymaster, Franklin Porter**
Brownsburg, Indiana 46112 (US)
• **Perry, Kenneth Wayne**
Indianapolis, Indiana 46227 (US)
• **Tollefson, Gary Dennis**
Indianapolis, Indiana 46236 (US)

(74) Representative: **Pritchard, Judith et al**
Eli Lilly and Company Limited
Lilly Research Centre
Erl Wood Manor
Windlesham, Surrey GU20 6PH (GB)

(56) References cited:
US-A- 5 229 382

- **SAXENA ET AL: "RISPERIDONE AUGMENTAION OF SRI TREATMENT FOR REFRACTORY OBSESSIVE- COMPULSIVE DISORDER" JOURNAL OF CLINICAL PSYCHIATRY, vol. 57, no. 7, July 1996, USA, pages 303-306, XP002052520**
- **DRYDEN-EDWARDS ET AL: "DIFFERENTIAL RESPONSE OF PSYCHOTIC AND OBSESSIVE SYMPTOMS TO RISPERICONE IN AN ADOLESCENT" JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, vol. 6, no. 2, July 1996, USA, pages 139-145, XP002052521**
- **CENTORRINO ET AL: "SERUM LEVELS OF CLOZAPINE AND NORCLOZAPINE IN PATIENTS TRATED WITH SLECTIVE SEROTONIN REUPTAKE INHIBITORS" AMERICAN JOURNAL OF PSYCHIATRY, vol. 153, no. 6, June 1996, USA, pages 820-822, XP002052522**
- **WOLTERS E CH ET AL: "OLANZAPINE IN THE TREATMENT OF DOPAMINOMIMETIC PSYCHOSIS IN PATIENTS WITH PARKINSON'S DISEASE" NEUROLOGY, vol. 47, no. 4, October 1996, pages 1085-1087, XP000673396**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 830 864 B9

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

[0001] The present invention relates to the use of olanzapine in combination with fluoxetine for the manufacture of a medicament for use in treating a patient suffering from or susceptible to psychosis, acute mania, mild anxiety states, or depression in combination with psychotic episodes.

[0002] Psychoses are serious mental illnesses characterized by defective or lost contact with reality. Psychotic patients may also suffer hallucinations and delusions as part of their disease. Psychoses exact a tremendous emotional and economic toll on the patients, their families, and society as a whole. While the mechanisms underlying these diverse disease states are poorly understood, recently discovered therapies are offering new hope for the treatment of psychotic patients. Progress in the treatment of psychotic conditions has been achieved through the introduction of new, atypical antipsychotic agents. While the side effect profile of these atypical antipsychotics is far superior to that of traditional agents, weight gain is a side effect that has been observed in patients treated with the atypical antipsychotics.

[0003] These new agents, while holding the promise of improving the lives of psychotic patients immeasurably, may not be sufficient to treat every psychotic patient. Since psychotic conditions appear to have a complex etiology, some schizophrenics which exhibit depressive episodes during the course of their illness, or depressed individuals which also have psychotic episodes, may not find total relief using only an atypical antipsychotic agent.~~[deletion(s)]~~

[0004] In this document, all temperatures are described in degrees Celsius, and all amounts, ratios of amounts and concentrations are described in weight units unless otherwise stated.

The Compounds ~~[deletion(s)]~~

[0005] Olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, is a known compound and is described in U.S. Patent No. 5,229,382 as being useful for the treatment of schizophrenia, schizophreniform disorder, acute mania, mild anxiety states, and psychosis. U.S. Patent No. 5,229,382 is herein incorporated by reference in its entirety.~~[deletion(s)]~~

[0006] Fluoxetine, N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, is marketed in the hydrochloride salt form, and as the racemic mixture of its two enantiomers. U.S. Patent 4,314,081 is an early reference on the compound. Robertson et al., J. Med. Chem. 31, 1412 (1988), taught the separation of the R and S enantiomers of fluoxetine and showed that their activity as serotonin uptake inhibitors is similar to each other. In this document, the word "fluoxetine" will be used to mean any acid addition salt or the free base, and to include either the racemic mixture or either of the R and S enantiomers.~~[deletion(s)]~~

[0007] It is preferred that olanzapine, is in the Form II olanzapine polymorph having a typical x-ray powder diffraction pattern as represented by the following interplanar spacings:

d
10.2689
8.577
7.4721
7.125
6.1459
6.071
5.4849
5.2181
5.1251
4.9874
4.7665
4.7158
4.4787
4.3307
4.2294
4.141
3.9873
3.7206
3.5645

EP 0 830 864 B9 (W1B1)

(continued)

d

3.5366

5

3.3828

3.2516

3.134

3.0848

3.0638

10

3.0111

2.8739

2.8102

2.7217

15

2.6432

2.6007

[0008] A typical example of an x-ray diffraction pattern for Form II is as follows wherein d represents the interplanar spacing and I/I_1 represents the typical relative intensities:

20

d	I/I_1
10.2689	100.00
8.577	7.96
7.4721	1.41
7.125	6.50
6.1459	3.12
6.071	5.12
5.4849	0.52
5.2181	6.86
5.1251	2.47
4.9874	7.41
4.7665	4.03
4.7158	6.80
4.4787	14.72
4.3307	1.48
4.2294	23.19
4.141	11.28
3.9873	9.01
3.7206	14.04
3.5645	2.27
3.5366	4.85
3.3828	3.47
3.2516	1.25
3.134	0.81
3.0848	0.45
3.0638	1.34
3.0111	3.51
2.8739	0.79
2.8102	1.47
2.7217	0.20
2.6432	1.26
2.6007	0.77

25

30

35

40

45

50

55

[0009] The x-ray diffraction patterns set out herein were obtained using a Siemens D5000 x-ray powder diffractometer

EP 0 830 864 B9 (W1B1)

having a copper K_{α} radiation source of wavelength, $\lambda = 1.541 \text{ \AA}$.

[0010] It is further preferred that the Form II olanzapine polymorph will be administered as the substantially pure Form II olanzapine polymorph.

[0011] As used herein "substantially pure" refers to Form II associated with less than about 5% Form I, preferably less than about 2% Form I, and more preferably less than about 1% Form I. Further, "substantially pure" Form II will contain less than about 0.5% related substances, wherein "related substances" refers to undesired chemical impurities or residual solvent or water. In particular, "substantially pure" Form II should contain less than about 0.05% content of acetonitrile, more preferably, less than about 0.005% content of acetonitrile. Additionally, the polymorph of the invention should contain less than 0.5% of associated water.

[0012] The polymorph obtainable by the process taught in the '382 patent will be designated as Form I and has a typical x-ray powder diffraction pattern substantially as follows, obtained using a Siemens D5000 x-ray powder diffractometer, wherein d represents the interplanar spacing:

	d
15	9.9463
	8.5579
	8.2445
	6.8862
20	6.3787
	6.2439
	5.5895
	5.3055
	4.9815
25	4.8333
	4.7255
	4.6286
	4.533
30	4.4624
	4.2915
	4.2346
	4.0855
	3.8254
35	3.7489
	3.6983
	3.5817
	3.5064
	3.3392
40	3.2806
	3.2138
	3.1118
	3.0507
45	2.948
	2.8172
	2.7589
	2.6597
	2.6336
50	2.5956

[0013] A typical example of an x-ray diffraction pattern for Form I is as follows wherein d represents the interplanar spacing and I/I_1 represents the typical relative intensities:

d	I/I_1
9.9463	100.00

EP 0 830 864 B9 (W1B1)

(continued)

d	I/I ₁
8.5579	15.18
8.2445	1.96
6.8862	14.73
6.3787	4.25
6.2439	5.21
5.5895	1.10
5.3055	0.95
4.9815	6.14
4.8333	68.37
4.7255	21.88
4.6286	3.82
4.533	17.83
4.4624	5.02
4.2915	9.19
4.2346	18.88
4.0855	17.29
3.8254	6.49
3.7489	10.64
3.6983	14.65
3.5817	3.04
3.5064	9.23
3.3392	4.67
3.2806	1.96
3.2138	2.52
3.1118	4.81
3.0507	1.96
2.948	2.40
2.8172	2.89
2.7589	2.27
2.6597	1.86
2.6336	1.10
2.5956	1.73


[0014] The x-ray powder diffraction patterns herein were obtained with a copper K_α of wavelength $\lambda = 1.541\text{\AA}$. The interplanar spacings in the column marked "d" are in Angstroms. The typical relative intensities are in the column marked "I/I₁".

[0015] Though Form II olanzapine is preferred it will be understood that as used herein, the term "olanzapine" embraces all solvate and polymorphic forms unless specifically indicated.

Preparation 1

Technical Grade olanzapine

[0016]



Intermediate 1

[0017] In a suitable three neck flask the following was added:

Dimethylsulfoxide (analytical)	6 volumes
Intermediate 1	75 g
N-Methylpiperazine (reagent)	6 equivalents

Intermediate 1 can be prepared using methods known to the skilled artisan. For example, the preparation of the Intermediate 1 is taught in the '382 patent.

[0018] A sub-surface nitrogen sparge line was added to remove the ammonia formed during the reaction. The reaction was heated to 120°C and maintained at that temperature throughout the duration of the reaction. The reactions were followed by HPLC until ² 5% of the intermediate 1 was left unreacted. After the reaction was complete, the mixture was allowed to cool slowly to 20°C (about 2 hours). The reaction mixture was then transferred to an appropriate three neck round bottom flask and water bath. To this solution with agitation was added 10 volumes reagent grade methanol and the reaction was stirred at 20°C for 30 minutes. Three volumes of water was added slowly over about 30 minutes. The reaction slurry was cooled to zero to 5°C and stirred for 30 minutes. The product was filtered and the wet cake was washed with chilled methanol. The wet cake was dried in vacuo at 45°C overnight. The product was identified as technical olanzapine.

Yield: 76.7%; Potency: 98.1%

Preparation 2

Form II olanzapine polymorph

[0019] A 270 g sample of technical grade 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine was suspended in anhydrous ethyl acetate (2.7 L). The mixture was heated to 76°C and maintained at 76°C for 30 minutes. The mixture was allowed to cool to 25°C. The resulting product was isolated using vacuum filtration. The product was identified as Form II using x-ray powder analysis. Yield: 197 g.

[0020] The process described above for preparing Form II provides a pharmaceutically elegant product having potency $\geq 97\%$, total related substances $< 0.5\%$ and an isolated yield of $> 73\%$.

[0021] It will be understood by the skilled reader that most or all of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of

all of the compounds are included in the names of them.

[0022] Many of the compounds used in this invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Since some of the free amines of the compounds of this invention are typically oils at room temperature, it is preferable to convert the free amines to their pharmaceutically acceptable acid addition salts for ease of handling and administration, since the latter are routinely solid at room temperature. Acids commonly employed to form such salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β -hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid, oxalic acid or fumaric acid.

Administration

[0023] The dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient. General outlines of the dosages, and some preferred dosages, can and will be provided here. Dosage guidelines for some of the drugs will first be given separately; in order to create a guideline for any desired combination, one would choose the guidelines for each of the component drugs.

Olanzapine: from 0.25 to 50 mg, once/day; preferred, from 1 to 30 mg, once/day; and most preferably 1 to 25 mg once/day. ~~[deletion(s)]~~

[0024] The adjunctive therapy of the present invention is carried out by administering olanzapine together with fluoxetine in any manner which provides effective levels of the compounds in the body at the same time. All of the compounds concerned are orally available and are normally administered orally, and so oral administration of the adjunctive combination is preferred. They may be administered together, in a single dosage form, or may be administered separately.

[0025] However, oral administration is not the only route or even the only preferred route. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. One of the drugs may be administered by one route, such as oral, and the others may be administered by the transdermal, percutaneous, intravenous, intramuscular, intranasal or intrarectal route, in particular circumstances. The route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver.

[0026] The adjunctive combination may be administered as a single pharmaceutical composition, and so pharmaceutical compositions incorporating both compounds are important embodiments of the present invention. Such compositions may take any physical form which is pharmaceutically acceptable, but orally usable pharmaceutical compositions are particularly preferred. Such adjunctive pharmaceutical compositions contain an effective amount of each of the compounds, which effective amount is related to the daily dose of the compounds to be administered. Each adjunctive dosage unit may contain the daily doses of all compounds, or may contain a fraction of the daily doses, such as one-third of the doses. Alternatively, each dosage unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compounds. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compounds. The amounts of each drug to be contained in each dosage unit depends on the identity of the drugs chosen for the therapy, and other factors such as the indication for which the adjunctive therapy is being given.

[0027] The inert ingredients and manner of formulation of the adjunctive pharmaceutical compositions are conventional, except for the presence of the combination of the present invention. The usual methods of formulation used in pharmaceutical science may be used here. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions. In general, compositions contain from 0.5% to 50% of the compounds in total, depending on the desired doses and the type of composition to be used. The amount of the compounds, however, is best defined as the effective amount, that is, the amount of each compound which provides the desired dose to the

patient in need of such treatment. The activity of the adjunctive combinations do not depend on the nature of the composition, so the compositions are chosen and formulated solely for convenience and economy. Any of the combinations may be formulated in any desired form of composition. Some discussion of different compositions will be provided, followed by some typical formulations.

[0028] Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.

[0029] Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidone and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

[0030] A lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.

[0031] Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, alginates and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used, as well as sodium lauryl sulfate.

[0032] Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in acid environments, and soluble in basic environments. Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate. **[deletion(s)]**

[0033] Tablets are often coated with sugar as a flavor and sealant. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established practice. Instantly dissolving tablet-like formulations are also now frequently used to assure that the patient consumes the dosage form, and to avoid the difficulty in swallowing solid objects that bothers some patients.

[0034] When it is desired to administer the combination as a suppository, the usual bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use, also.

[0035] Transdermal patches have become popular recently. Typically they comprise a resinous composition in which the drugs will dissolve, or partially dissolve, which is held in contact with the skin by a film which protects the composition. Many patents have appeared in the field recently. Other, more complicated patch compositions are also in use, particularly those having a membrane pierced with innumerable pores through which the drugs are pumped by osmotic action.

[0036] The following typical formulae are provided for the interest and information of the pharmaceutical scientist.

Formulation 1

[0037] Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Olanzapine	25 mg
Fluoxetine, racemic, hydrochloride	20
Starch, dried	150
Magnesium stearate	10
Total	210 mg

Formulation 2

[0038] A tablet is prepared using the ingredients below:

	Quantity (mg/capsule)
Olanzapine	10
Fluoxetine, racemic, hydrochloride	10
Cellulose, microcrystalline	275
Silicon dioxide, fumed	10
Stearic acid	<u>5</u>
Total	310 mg

The components are blended and compressed to form tablets each weighing 465 mg. ~~[deletion(s)]~~

Benefit of the Invention

[0039] The present invention provides the advantage of treatment of psychotic conditions and mild anxiety with the atypical antipsychotics without the concomitant weight gain typically observed with such treatment, conferring a marked and unexpected benefit on the patient. The present invention furthermore provides a potentiation of the increase in the concentration of norepinephrine observed as an effect of administration olanzapine by administration of fluoxetine.

[0040] The present invention is particularly suited for use in the treatment of bipolar disorders, mania (mixed state), schizoaffective disorders characterized by the occurrence of a depressive episode during the period of illness, and depression with psychotic features. Such disorders may often be resistant to treatment with an antipsychotic alone.

[0041] The present invention also is useful for the treatment of premenstrual syndrome (PMS) and anorexia nervosa. Furthermore, the present invention is useful for the treatment of the aggression/violence which may be associated with certain disorders. These disorders include, mania, schizophrenia, schizoaffective disorders, substance abuse, head injury, and mental retardation.

[0042] Psychotic conditions to be treated by the present method of adjunctive therapy include schizophrenia, schizophreniform diseases, acute mania, schizoaffective disorders, and depression with psychotic features. The titles given these conditions represent multiple disease states. The following list illustrates a number of these disease states, many of which are classified in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM). The DSM code numbers for these disease states are supplied below, when available, for the convenience of the reader.

Paranoid Type Schizophrenia 295.30
 Disorganized Type Schizophrenia 295.10
 Catatonic Type Schizophrenia 295.20
 Undifferentiated Type Schizophrenia 295.90
 Residual Type Schizophrenia 295.60
 Schizophreniform Disorder 295.40
 Schizoaffective Disorder 295.70
 Schizoaffective Disorder of the Depressive Type
 Major Depressive Disorder with Psychotic Features 296.24, 296.34

[0043] Psychoses are often associated with other diseases and conditions, or caused by such other conditions. For example, they are associated with neurological conditions, endocrine conditions, metabolic conditions, fluid or electrolyte imbalances, hepatic or renal diseases, and autoimmune disorders with central nervous system involvement. Psychoses may also be associated with use or abuse of certain substances. These substances include, cocaine, methylphenidate, dexamethasone, amphetamine and related substances, cannabis, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics and anxiolytics. Psychotic disorders may also occur in association with withdrawal from certain substances. These substances include, sedatives, hypnotics and anxiolytics. The embodiments of the present invention are useful for treatment of psychotic conditions associated with any of these conditions.

Microdialysis assays of monoamines

[0044] Sprague-Dawley rats (Harlan or Charles River) weighing 270-300 grams are surgically implanted with microdialysis probes under chloral hydrate/pentobarbital anesthesia (170 and 36 mg/kg i.p. in 30% propylene glycol, 14% ethanol) (Perry and Fuller, Effect of fluoxetine on serotonin and dopamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan. Life Sci., 50, 1683-90 (1992)). A David Kopf stereotaxic in-

strument is used to implant the probe unilaterally in the hypothalamus at coordinates rostral -1.5 mm, lateral -1.3 mm, and ventral -9.0 mm (Paxinos and Watson, 1986). After a 48 hour recovery period, rats are placed in a large plastic bowl with a mounted liquid swivel system (CMA/120 system for freely moving animals, Bioanalytical Systems, West Lafayette, IN). Filtered artificial cerebrospinal fluid (CSF) (150 mM NaCl, 3.0 mM KCl, 1.7 mM CaCl₂, and 0.9 mM MgCl₂) is perfused through the probe at a rate of 1.0 ml/min. The output dialysate line is fitted to a tenport HPLC valve with a 20 µl loop. At the end of each 30 minute sampling period, dialysate collected in the loop is injected on an analytical column (Spherisorb 3 µ ODS2, 2X150 mm, Keystone Scientific).

[0045] The method used to measure monoamines is as described by Perry and Fuller (1992). Briefly, dialysate collected in the 20 µl loop is assayed for 5-HT, NE and DA. The 20 µl injection goes onto the column with a mobile phase which resolves NE, DA, and 5-HT: 75 mM potassium acetate, 0.5 mM ethylenediaminetetraacetic acid, 1.4 mM sodium octanesulfonic acid and 8% methanol, pH 4.9. The mobile phase for the amine column is delivered with a flow programmable pump at an initial flow rate of 0.2 ml/min increasing to 0.3 ml/min at 5 min then decreasing back to 0.2 ml/min at 26 min with a total run time of 30 min. Flow programming is used to elute the 5-HT within a 25 min time period. The electrochemical detector (EG&G, Model 400) for the amine column is set at a potential of 400 mV and a sensitivity of 0.2 nA/V. Basal levels are measured for at least 90 minutes prior to drug administration. The drugs are prepared in filtered deionized water (volume 0.25-0.3 ml) for administration at the desired doses.

Claims

1. Use of olanzapine in combination with fluoxetine for the manufacture of a medicament for use in treating a patient suffering from or susceptible to psychosis, acute mania, mild anxiety states, bipolar disorder or depression in combination with psychotic episodes.
2. Use of Claim 1 wherein the olanzapine component is Form II olanzapine.
3. Use of Claim 1 or 2 wherein the patient is suffering from schizophrenia.
4. Use of Claim 1 or 2 wherein the patient is suffering from a schizoaffective disorder.
5. Use of Claims 1 to 4 wherein the patient is suffering from Paranoid Type Schizophrenia 295.30.
6. Use of Claims 1 to 4 wherein the patient is suffering from Disorganized Type Schizophrenia 295.10.
7. Use of Claims 1 to 4 wherein the patient is suffering from Catatonic Type Schizophrenia 295.20.
8. Use of Claims 1 to 4 wherein the patient is suffering from Undifferentiated Schizophrenia Type 295.90.
9. Use of Claims 1 to 4 wherein the patient is suffering from Schizophrenia Residual Type Schizophrenia 295.60.
10. Use of Claims 1 to 4 wherein the patient is suffering from Schizophreniform Disorder 295.40.
11. Use of Claims 1 to 4 wherein the patient is suffering from Schizoaffective Disorder 295.70.
12. Use of Claims 1 to 4 wherein the patient is suffering from Schizoaffective Disorder of the Depressive Type.
13. Use of Claims 1 to 4 wherein the patient is suffering from Major Depressive Disorder with Psychotic Features 296.24, 296.34.
14. Use of Claims 1 or 2 wherein the patient is suffering from mania (mixed state) or a bipolar disorder resistant to treatment with an antipsychotic alone.
15. Use of Claims 1 to 4 wherein the patient is suffering from a schizoaffective disorder **characterized by** the occurrence of a depressive episode during the period of illness, or a schizoaffective disorder **characterized by** the occurrence of a depressive episode during the period of illness resistant to treatment with an antipsychotic alone.
16. Use of Claims 1 or 2 wherein the patient is suffering from premenstrual syndrome (PMS) or anorexia nervosa.

17. Use of Claims 1 or 2 wherein the patient is suffering from a treatment of the aggression/violence associated with disorder selected from the group consisting of mania, schizophrenia, schizoaffective disorders, substance abuse, head injury, and mental retardation.

18. Use of Claims 1 or 2 wherein the patient is suffering from psychosis associated with neurological conditions, endocrine conditions, metabolic conditions, fluid or electrolyte imbalances, hepatic or renal diseases; or an autoimmune disorder with central nervous system involvement.

19. Use of Claims 1 or 2 wherein the patient is suffering from psychosis associated with use or abuse of substances selected from the group consisting of cocaine, methylphenidate, dexamethasone, amphetamine and related substances, cannabis, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics and anxiolytics.

20. Use of Claims 1 or 2 wherein the patient is suffering from psychotic disorder in association with withdrawal from the group consisting of sedatives, hypnotics and anxiolytics.

21. Use according to any one of claims 1 to 20, wherein fluoxetine is in the hydrochloride salt form.

22. A pharmaceutical composition which comprises a first component which is olanzapine, and a second component which is fluoxetine hydrochloride.

23. A pharmaceutical composition as claimed in claim 22 containing from 1 to 25 mg. of olanzapine and from 1 to 80 mg. of fluoxetine hydrochloride.

24. A pharmaceutical composition as claimed in claim 23 containing 10 to 40 mg. of fluoxetine hydrochloride.

25. A pharmaceutical composition as claimed in claim 23 containing from 20 to 80 mg. of fluoxetine hydrochloride.

Patentansprüche

1. Verwendung von Olanzapin in Kombination mit Fluoxetin zur Herstellung eines Arzneimittels zur Verwendung bei der Behandlung eines Patienten, der an Psychose, akuter Manie, leichten Angstzuständen, bipolaren Störungen oder Depression in Kombination mit psychotischen Episoden leidet oder hierfür empfindlich ist.

2. Verwendung nach Anspruch 1, worin die Olanzapinkomponente Olanzapin der Form II ist.

3. Verwendung nach Anspruch 1 oder 2, worin der Patient an Schizophrenie leidet.

4. Verwendung nach Anspruch 1 oder 2, worin der Patient an einer schizoaffectiven Störung leidet.

5. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an der Schizophrenie vom paranoiden Typ 295.30 leidet.

6. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer Schizophrenie vom unorganisierten Typ 295.10 leidet.

7. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer Schizophrenie vom katatonischen Typ 295.20 leidet.

8. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer Schizophrenie vom undifferenzierten Typ 295.90 leidet.

9. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer Schizophrenie vom Residualtyp 295.60 leidet.

10. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer schizophrenieartigen Störung 295.40 leidet.

11. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer schizoaffektiven Störung 295.70 leidet
12. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer schizoaffektiven Störung des depressiven Typs leidet.
13. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer vorwiegend depressiven Störung mit psychotischen Merkmalen 296.24, 296.34 leidet.
14. Verwendung nach Anspruch 1 oder 2, worin der Patient an einer Manie (gemischter Zustand) oder einer bipolaren Störung leidet, die gegenüber einer alleinigen Behandlung mit einem Antipsychotikum resistent ist.
15. Verwendung nach einem der Ansprüche 1 bis 4, worin der Patient an einer schizoaffektiven Störung leidet, die durch das Auftreten einer depressiven Episode während der Krankheitsperiode charakterisiert ist oder einer schizoaffektiven Störung, die durch das Auftreten der depressiven Episode während der Krankheitsperiode charakterisiert ist, die gegenüber einer alleinigen Behandlung mit einem Antipsychotikum resistent ist.
16. Verwendung nach einem der Ansprüche 1 oder 2, worin der Patient an einem prämenstruellen Syndrom (PMS) oder an Anorexia nervosa leidet.
17. Verwendung nach einem der Ansprüche 1 oder 2, worin der Patient an einer Behandlung der Aggression / Gewalt leidet, die mit einer Störung assoziiert ist, ausgewählt aus der Gruppe, die besteht aus Manie, Schizophrenie, schizoaffektiven Störungen, Substanzmißbrauch, Kopfverletzung und mentaler Retardierung.
18. Verwendung nach Anspruch 1 oder 2, worin der Patient an einer Psychose leidet, die assoziiert ist mit neurologischen Zuständen, endokrinen Zuständen, metabolischen Zuständen, Flüssigkeits- oder Elektrolytungleichgewichten. Leber- oder Nierenerkrankungen oder einer autoimmunen Störung mit einer Beteiligung des zentralen Nervensystems.
19. Verwendung nach Anspruch 1 oder 2, worin der Patient an einer Psychose leidet, die mit dem Gebrauch oder Mißbrauch an Substanzen assoziiert ist, ausgewählt aus der Gruppe, die besteht aus Kokain, Methylphenidat, Dexamethason, Amphetamin und verwandten Substanzen, Kannabis, Halluzinogenen, Inhalationsmittel, Opioiden, Phencyclidin, Sedativa, Hypnotika und Anxiolytika.
20. Verwendung nach Anspruch 1 oder 2, worin der Patient an psychotischen Störungen zusammen mit dem Entzug der Substanzgruppe, die besteht aus Sedativa, Hypnotika und Anxiolytika leidet.
21. Verwendung nach einem der Ansprüche 1 bis 20, worin Fluoxetin in der Hydrochloridsalzform vorliegt.
22. Pharmazeutische Zusammensetzung, die umfaßt eine erste Komponente, die Olanzapin ist, und eine zweite Komponente, die Fluoxetinhydrochlorid ist.
23. Pharmazeutische Zusammensetzung nach Anspruch 22, die 1 bis 25 mg Olanzapin und 1 bis 80 mg Fluoxetinhydrochlorid enthält.
24. Pharmazeutische Zusammensetzung nach Anspruch 23, die 10 bis 40 mg Fluoxetinhydrochlorid enthält.
25. Pharmazeutische Zusammensetzung nach Anspruch 23, die 20 bis 80 mg Fluoxetinhydrochlorid enthält.

Revendications

1. Utilisation d'olanzapine en combinaison avec de la fluoxétine pour la préparation d'un médicament à utiliser dans le traitement d'un patient souffrant de psychose, de manie aiguë, d'anxiété bénigne, de troubles bipolaires ou de dépression en combinaison avec des épisodes psychotiques ou d'un patient sensible auxdits troubles.
2. Utilisation selon la revendication 1, dans laquelle le composant d'olanzapine est de l'olanzapine de forme II.
3. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre de schizophrénie.

EP 0 830 864 B9 (W1B1)

4. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre de schizophrénie dysthymique.
- 5 5. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie 295.30 de type paranoïde.
- 6 6. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie 295.10 de type perturbé.
- 7 7. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie 295.20 de type catatonique.
- 10 8. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie non différenciée de type 295.90.
- 15 9. Utilisation selon l'une quelconque des revendications 1 à 4, dans laquelle le patient souffre de schizophrénie résiduelle de type 295.60.
- 10 10. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de troubles schizophréniformes 295.40.
- 20 11. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie dysthymique 295.70.
- 12 12. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie dysthymique de type dépressif.
- 25 13. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de troubles dépressifs majeurs avec les caractéristiques psychotiques 296.24, 296.34.
- 14 14. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre de manie (état mêlé) ou d'un trouble bipolaire résistant à un traitement avec un antipsychotique seul.
- 30 15. Utilisation selon les revendications 1 à 4, dans laquelle le patient souffre de schizophrénie dysthymique **caractérisée par** l'apparition d'un épisode de dépression au cours de la période de la maladie, ou de schizophrénie dysthymique **caractérisée par** l'apparition d'un épisode de dépression au cours de la période de la maladie, résistant à un traitement avec un antipsychotique seul.
- 35 16. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre du syndrome prémenstruel (PMS) ou d'anorexie nerveuse.
- 17 17. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre d'un traitement de l'agression/la violence associée à un trouble choisi parmi le groupe constitué par la manie, la schizophrénie, la schizophrénie dysthymique, l'abus de drogues, un traumatisme cranio-cérébral et une arriération mentale.
- 40 18. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre d'une psychose associée à des troubles neurologiques, à des troubles endocriniens, à des troubles métaboliques, à des déséquilibres hydroélectriques, à des troubles hépatiques ou rénaux ou à des troubles autoimmunitaires impliquant le système nerveux central.
- 45 19. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre de psychose associée à l'utilisation ou à l'abus de substances choisies parmi le groupe constitué par la cocaïne, le phénidate de méthyle, la dexaméthasone, les amphétamines et les substances apparentées, le cannabis, des substances hallucinogènes, des produits pour inhalation, des opioïdes, la phencyclidine, des sédatifs, des somnifères et des anxiolytiques.
- 50 20. Utilisation selon la revendication 1 ou 2, dans laquelle le patient souffre d'un trouble psychotique en relation avec le sevrage d'une substance choisie parmi le groupe constitué par des sédatifs, des somnifères et des anxiolytiques.
- 55 21. Utilisation selon l'une quelconque des revendications 1 à 20, dans laquelle la fluoxétine se présente sous la forme de son sel chlorhydrate.
22. Composition pharmaceutique qui comprend un premier composant à savoir de l'olanzapine et un deuxième composant à savoir le chlorhydrate de fluoxétine.

EP 0 830 864 B9 (W1B1)

23. Composition pharmaceutique selon la revendication 22, contenant de l'olanzapine à concurrence de 1 à 25 mg et du chlorhydrate de fluoxétine à concurrence de 1 à 80 mg.

5 **24.** Composition pharmaceutique selon la revendication 23, contenant du chlorhydrate de fluoxétine à concurrence de 10 à 40 mg.

25. Composition pharmaceutique selon la revendication 23, contenant du chlorhydrate de fluoxétine à concurrence de 20 à 80 mg.

10

15

20

25

30

35

40

45

50

55